Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $401.65 million. The enterprise value is $352.23 million.
Important Dates
The next confirmed earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 48.92 million shares outstanding. The number of shares has decreased by -24.30% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.92M |
| Shares Change (YoY) | -24.30% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 8.02% |
| Owned by Institutions (%) | 45.47% |
| Float | 21.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.21 |
| PS Ratio | 6.57 |
| Forward PS | 9.36 |
| PB Ratio | 2.07 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.20 |
| Quick Ratio | 4.81 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.55 |
Financial Efficiency
Return on equity (ROE) is -19.27% and return on invested capital (ROIC) is -8.51%.
| Return on Equity (ROE) | -19.27% |
| Return on Assets (ROA) | -6.02% |
| Return on Capital (ROIC) | -8.51% |
| Revenue Per Employee | $626,434 |
| Profits Per Employee | -$461,141 |
| Employee Count | 99 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $7.43 million in taxes.
| Income Tax | 7.43M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.65% in the last 52 weeks. The beta is 0.25, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -16.65% |
| 50-Day Moving Average | 8.25 |
| 200-Day Moving Average | 8.82 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 140,036 |
Short Selling Information
The latest short interest is 5.04 million, so 10.30% of the outstanding shares have been sold short.
| Short Interest | 5.04M |
| Short Previous Month | 5.24M |
| Short % of Shares Out | 10.30% |
| Short % of Float | 23.79% |
| Short Ratio (days to cover) | 24.51 |
Income Statement
In the last 12 months, TBPH had revenue of $62.02 million and -$45.65 million in losses. Loss per share was -$0.92.
| Revenue | 62.02M |
| Gross Profit | 26.47M |
| Operating Income | -38.96M |
| Pretax Income | -38.22M |
| Net Income | -45.65M |
| EBITDA | -39.18M |
| EBIT | -38.96M |
| Loss Per Share | -$0.92 |
Full Income StatementBalance Sheet
The company has $96.08 million in cash and $46.66 million in debt, giving a net cash position of $49.42 million or $1.01 per share.
| Cash & Cash Equivalents | 96.08M |
| Total Debt | 46.66M |
| Net Cash | 49.42M |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 193.69M |
| Book Value Per Share | 3.96 |
| Working Capital | 96.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.78 million and capital expenditures -$825,000, giving a free cash flow of -$9.60 million.
| Operating Cash Flow | -8.78M |
| Capital Expenditures | -825,000 |
| Free Cash Flow | -9.60M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 42.68%, with operating and profit margins of -62.82% and -73.61%.
| Gross Margin | 42.68% |
| Operating Margin | -62.82% |
| Pretax Margin | -61.63% |
| Profit Margin | -73.61% |
| EBITDA Margin | -63.17% |
| EBIT Margin | -62.82% |
| FCF Margin | -15.48% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 24.30% |
| Shareholder Yield | 24.30% |
| Earnings Yield | -11.37% |
| FCF Yield | -2.39% |
Analyst Forecast
The average price target for TBPH is $13.75, which is 67.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.75 |
| Price Target Difference | 67.48% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 30.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TBPH has an Altman Z-Score of -1.76 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.76 |
| Piotroski F-Score | 3 |